Filtered By:
Source: European Journal of Heart Failure
Management: Health Insurance
Therapy: Dialysis
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 1 results found since Jan 2013.
The Effects of Mineralocorticoid Receptor Antagonists on Cardiovascular Outcomes in Patients With End ‐Stage Renal Disease and Heart Failure
ConclusionsIn patients undergoing regular dialysis who are diagnosed with heart failure, the use of MRAs is associated with lower risks of all-cause mortality and CV death. The benefits of MRA treatment in heart failure may persist in patients with ESRD. Further investigations through randomized controlled trials are needed to assess the efficacy and safety of MRAs in this high-risk population.This article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - November 21, 2022 Category: Cardiology Authors: Donna Shu ‐Han Lin,
Fang‐Ju Irene Lin,
Yu‐Sheng Lin,
Jen‐Kuang Lee,
Yen‐Hung Lin Tags: Research Article Source Type: research
